Abstract
Mechanistic population balance modeling (PBM) has advanced the design of pharmaceutical crystallization processes, enabling the production of active pharmaceutical ingredient (API) crystals with desired critical quality attributes (CQAs), such as purity and crystal size distribution. However, PBM development can sometimes be resource-intensive, requiring extensive design of experiments (DoE) and high-quality process data, making it impractical under fast-paced industrial development timelines. This study proposes a machine learning (ML)-based workflow for developing ‘fit-for-purpose’ digital twins of crystallization processes, leveraging industrially available DoE data to link operating conditions with CQAs. Validated on industrial data for a commercial API with complex crystallization challenges, the workflow efficiently identifies optimal operating conditions, demonstrating the potential of data-driven digital twins to accelerate the development of pharmaceutical processes.